Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. (2025). Journal of Kidney Cancer, 12(4), 7-18. https://doi.org/10.15586/jkcvhl.v12i4.403